Netarsudil trial completes enrollment in Japan

Aerie Pharmaceuticals has completed enrollment in a phase 2 clinical trial of netarsudil ophthalmic solution in Japan, according to a press release.

The prospective, double-masked, multicenter, placebo-controlled, parallel group trial includes 215 patients randomly assigned to one of four treatment arms: netarsudil 0.01%, 0.02% or 0.04% or placebo, administered once daily in the evening.

“We believe this rapid enrollment reflects the enthusiasm of the clinical investigators at the 25 centers across Japan that participated in the study and is a credit to our clinical operations teams in Tokyo and the United States,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We expect to have topline data from this study in fourth-quarter 2019, allowing us to confirm the concentration of netarsudil we will take forward into phase 3 trials in Japan.”

The study is evaluating the IOP-reducing effect and safety of netarsudil in patients with glaucoma and ocular hypertension over a 28-day period.

Aerie Pharmaceuticals has completed enrollment in a phase 2 clinical trial of netarsudil ophthalmic solution in Japan, according to a press release.

The prospective, double-masked, multicenter, placebo-controlled, parallel group trial includes 215 patients randomly assigned to one of four treatment arms: netarsudil 0.01%, 0.02% or 0.04% or placebo, administered once daily in the evening.

“We believe this rapid enrollment reflects the enthusiasm of the clinical investigators at the 25 centers across Japan that participated in the study and is a credit to our clinical operations teams in Tokyo and the United States,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We expect to have topline data from this study in fourth-quarter 2019, allowing us to confirm the concentration of netarsudil we will take forward into phase 3 trials in Japan.”

The study is evaluating the IOP-reducing effect and safety of netarsudil in patients with glaucoma and ocular hypertension over a 28-day period.